Gurgaon Samachar

Sarcopenia Pipeline Insight, 2020 By DelveInsight

 Breaking News
  • No posts were found

Sarcopenia Pipeline Insight, 2020 By DelveInsight

August 01
01:19 2020
Sarcopenia Pipeline Insight, 2020 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Sarcopenia Pipeline

Sarcopenia Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Sarcopenia market. A detailed picture of the Sarcopenia pipeline landscape is provided, which includes the disease overview and Sarcopenia treatment guidelines. The assessment part of the report embraces in-depth Sarcopenia commercial assessment and clinical assessment of the Sarcopenia pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sarcopenia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Sarcopenia is a condition which is characterized by loss of muscle mass, muscle strength and functional muscle impairment with ageing. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases. The etiology of sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distibution), reduced anabolic hormone levels, muscle disuse, and inflammation driven by environmental, genetic and behavioral factors



Request for free sample page:-


Sarcopenia Pipeline Development Activities

 The report provides insights into: 

  • All of the companies that are developing therapies for the treatment of Sarcopenia with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Sarcopenia treatment.
  • Sarcopenia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Sarcopenia market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc


Sarcopenia Pipeline

Research is underway to identify therapeutic targets and develop a curative therapy for the treatment of sarcopenia. But, the current sarcopenia pipeline is poor with very few industry-funded trials. Some of the potential candidates are elaborated below.

  • Biophytis’ lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases. Preclinical data demonstrated that Sarconeos (BIO101) for the treatment of sarcopenia has beneficial effects on muscle function and increases muscle strength and mobility in animal models. It activates the MAS receptor in muscle cells, a key component of the Renin-Angiotensin System (RAS). 
  • Novartis “breakthrough” drug bimagrumab is currently being evaluated for the treatment of sarcopenia and has demonstrated good safety and efficacy profile in phase III trials. Bimagrumab is a human monoclonal antibody that binds to type II activin receptors and prevents the binding of its ligands (e.g., myostatin, activin A).These ligands normally act as inhibitors of muscle growth and protein anabolism;bimagrumab lifts this inhibition and can increase muscle mass in young and older adults. However, one of its other major trials targeting sporadic Inclusion Body Myositis (sIBM) using the same drug candidate failed to meet its primary endpoints,and the program was discontinued in this disease in 2016. There have been no major trial related updates since 2018.
  • Amazentis’s AMAZ-02 is an oral formulation of urolithin A, a naturally occurring metabolite that has been shown to improve mitochondrial and muscle function through a process known as mitophagy. . Results from phase I studies indicate that urolithin A stimulates mitochondrial biogenesis in the same manner as exercise, and it is the only known compound able to reestablish cell’s ability to recycle defective mitochondria according to the researchers. Mitochondrial biogenesis is the process by which cells increase mitochondrial mass, this happens naturally in younger people but with age the body starts to lose the energy to clean up leftovers and dysfunctional mitochondria which could lead to eventual weakening of tissues and loss of muscle mass/sarcopenia. In April 2019 Nestlé Health Science announced that it has entered into a global strategic partnership with Amazentis to develop Urolithin A.Sarcopenia is a growing socio-economic burden due to the ongoing demographic shift and the aging of most societies, with no viable treatment to meet the global need.
  • The complexity is further added because no endpoint has been approved yet for the registration of a drug for sarcopenia or other muscle-wasting condition. However, the silver lining is that the health authorities are moving closer to accepting physical performance-based and patient-reported outcome assessments for use in drug trials. Overall, the muscle atrophy market is poised at a critical juncture. Antimyostatin agents have been in clinical trials for more than a decade, and SARMs even longer with little to present.

Emerging drugs included in the report

  • Sarconeos: Biophytis
  • Bimagrumab: Novartis
  • LY2495655: Eli Lily
  • Trevogrumab: Regeneron Pharmaceuticals/ Sanofi
  • PF 1801: Immunoforge
  • Enobosarm : GTx


Request for free sample page:-


Table of content

1. Report Introduction

2. Sarcopenia 

3. Sarcopenia Current Treatment Patterns

4. Sarcopenia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Sarcopenia Late Stage Products (Phase-III)

7. Sarcopenia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Sarcopenia Discontinued Products

13. Sarcopenia Product Profiles

14. Sarcopenia Key Companies

15. Sarcopenia Key Products

16. Dormant and Discontinued Products

17. Sarcopenia Unmet Needs

18. Sarcopenia Future Perspectives

19. Sarcopenia Analyst Review  

20. Appendix

21. Report Methodology

22. About DelveInsight

Related Reports

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/ on line 5